Y-mAbs Therapeutics (NASDAQ:YMAB) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $20.4, along with a high estimate of $25.00 and a low estimate of $11.00. Observing a 2.0% increase, the current average has risen from the previous average price target of $20.00….